Sulfaguanidine 500mg tablets
Requires a prescription from a doctor or prescriber
Sulfaguanidine is a sulfonamide antibiotic with antimicrobial and antibacterial activities.[A275108]
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Sulfaguanidine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Sulfaguanidine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 25 studies.
Reviews & meta-analyses: 2 · 2021–2025
Showing all 25 studies, sorted by most relevant.
Hamada S. Abulkhair
Archiv der Pharmazie, 2024
- Drug Development
- Guanidines
- Anti-Infective Agents
E. Husseiny, Hamada S Abulkhair, Nehad M. El-Dydamony, et al.
Bioorganic chemistry, 2023
- Antineoplastic Agents
- Pyrazoles
- Sulfaguanidine
Suleyman Akocak, Parham Taslimi, Nebih Lolak, et al.
Chemistry & Biodiversity, 2021
- Acetylcholinesterase
- alpha-Glucosidases
- Alzheimer Disease
Lolak N, Akocak S, Durgun M, et al.
2023
- Carbonic Anhydrases
- Acetylcholinesterase
- Carbonic Anhydrase Inhibitors
D. Najlaoui, M. Echabaane, A. Khelifa, et al.
Electrocatalysis, 2022
A. Ragab, Sawsan A. Fouad, O. Ali, et al.
Antibiotics, 2021
Herein, a series of novel hybrid sulfaguanidine moieties, bearing 2-cyanoacrylamide 2a–d, pyridine-2-one 3–10, and 2-imino-2H-chromene-3-carboxamide 11, 12 derivatives, were synthesized, and their structure confirmed by spectral data and elemental analysis. All the synthesized compounds showed moderate to good antimicrobial activity against eight pathogens. The most promising six derivatives, 2a, 2b, 2d, 3a, 8, and 11, revealed to be best in inhibiting bacterial and fungal growth, thus showing bactericidal and fungicidal activity. These derivatives exhibited moderate to potent inhibition against DNA gyrase and DHFR enzymes, with three derivatives 2d, 3a, and 2a demonstrating inhibition of DNA gyrase, with IC50 values of 18.17–23.87 µM, and of DHFR, with IC50 values of 4.33–5.54 µM; their potency is near to that of the positive controls. Further, the six derivatives exhibited immunomodulatory potential and three derivatives, 2d, 8, and 11, were selected for further study and displayed an increase in spleen and thymus weight and enhanced the activation of CD4+ and CD8+ T lymphocytes. Finally, molecular docking and some AMED studies were performed.
Abstract licence: CC BY
Shan Huang, Vinay K R Cheemarla, D. Tiana, et al.
Crystal Growth & Design, 2023
Pharmaceutical cocrystals, a type of multicomponent crystalline material incorporating two or more molecular and/or ionic compounds connected by noncovalent interactions (such as hydrogen bonds, π-π interactions, and halogen bonds), are attracting increasing attention in crystal engineering. Sulfaguanidine (SGD), one of the most frequently used sulfonamide compounds, was chosen as a model compound in this work to further investigate the hydrogen bond interactions in cocrystals, since it possesses various hydrogen bond donor and acceptor sites. Five cocrystals of SGD, synthesized successfully by slurry and slow evaporation methods, were fully characterized by thermal analysis, X-ray techniques, and Fourier transform infrared spectroscopy. To gain insight into the nature of hydrogen-bonding interactions, theoretical calculations including the analysis of Hirshfeld surface, MEPS (molecular electrostatic potential surface), and QTAIM (quantum theory of atoms in molecules) were conducted. The results are a part of a systematic study of cocrystals of sulfonamides that aims to establish synthon hierarchies in cocrystals containing molecules with multiple hydrogen-bonding functional groups.
Abstract licence: CC BY
Alelaimat MA, Al-Sha'er MA, Basheer HA
2023
The biological benefits of trisubstituted 1,3,5-triazine derivatives include their ability to reduce inflammation and fight cancer. A unique series of sulfonamide–triazine hybrid molecules were produced chemically by synthesizing triazine derivatives utilizing the usual nucleophilic aromatic substitution of cyanuric chloride via the solvent-free/neat fusion method. Fourier-transform infrared spectroscopy (FTIR), 1H NMR, and 13C NMR spectroscopic analyses were used to identify novel trisubstituted synthetic compounds. The synthesized compounds have a moderate inhibition percentage when tested at 100 μM against the phosphoinositol 3-kinases (PI3Kα) enzyme; compounds 20 and 34 showed 46 and 68% anti-PI3Kα activity, respectively. To comprehend the anticipated interactions, the most successful compounds were subsequently docked into a PI3Kα protein’s binding site (PDB code: 6OAC, resolution: 3.15 Å). The final synthetic compounds’ anticancer activity was tested on the breast (MCF-7) and lung (A549) cancer cell lines at doses of 100 and 50 μM for additional evaluation of anticancer characteristics. The IC50 values for the sulfaguanidine–triazine derivatives 27, 28, 29, 31, and 35 ranged from 14.8 to 33.2 μM, showing that compounds containing sulfaguanidine and diethylamine in their structures significantly inhibited the activity. Compound 34 could be a promising lead compound for developing new target-selected anticancer compounds with low toxicity and high selectivity.
Abstract licence: CC BY-NC-ND
A. Abdelmoniem, Mostafa E. Salem, M. Allam, et al.
Results in Chemistry, 2025
The synthesis of sulfa drugs has received extensive interest from researchers for their broad spectrum of biological activities. In this context, N -Carbamimidoyl-4-((5,5-dimethyl-3-oxocyclohex-1-en-1-yl)amino)benzenesulfonamide 3 was readily prepared and its Michael addition reactions towards activated cinnamonitriles were studied as a route to 4-(2-amino-3-cyano-4-aryl-tetrahydroquinolin-1-yl)- N -carbamimidoylbenzenesulfonamide derivatives 8a-d . Moreover, N -(4-( N -carbamimidoylsulfamoyl)phenyl)-2-cyanoacetamide 13 was prepared and employed as a precursor for the synthesis of 4-(6-amino-3,5-dicyano-2-oxo-4-arylpyridin-1-yl)- N -carbamimidoylbenzenesulfonamide derivatives 17a-e . Green synthesis of the targeted products was done in water in the presence of chitosan as a green catalyst and gave considerably higher yields as compared to conducting reactions in ethanol in presence of non-benign piperidine catalyst. The chemical constitution of all newly synthesized compounds was confirmed by the different spectral tools.
Abstract licence: CC BY-NC
Ola A. Abu Ali, A. Ragab, Y. Ammar, et al.
Journal of Molecular Structure, 2025
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
experimental
Major interactions
None known
Half-life
Not available
Mechanism
Sulfaguanidine is a sulfonamide antibacterial that inhibits dihydropteroate synt…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 113 interactions
ATC A07AB03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Sulfaguanidine
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q414886), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.